AIM
CHRS icon

Alambic Investment Management’s Coherus Oncology CHRS Stock Holding History

Alambic Investment Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-17,000
Closed -$479K – 636
2016
Q4 		$479K Buy
+17,000
New +$476K 0.09% 340

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Alambic Investment Management's CHRS Position: Q1 2017 in Review

Alambic Investment Management sold out of Coherus Oncology (CHRS) in Q1 2017, closing a stake of 17,000 shares — an estimated $479K sold.

Alambic Investment Management first reported a position in CHRS in Q4 2016 and held it in 1 quarter. The position peaked at $479K in Q4 2016. 109 funds tracked by Wall St. Rank hold CHRS as of Q1 2017.

  • Alambic Investment Management reported no remaining Coherus Oncology position as of Q1 2017 after selling out during the quarter.
  • Alambic Investment Management sold 17,000 Coherus Oncology shares in Q1 2017, an estimated $479K.
  • Alambic Investment Management first reported a position in Coherus Oncology in Q4 2016 and held it in 1 quarter.
  • Alambic Investment Management's Coherus Oncology position peaked at $479K in Q4 2016.
  • 109 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2017.

Based on Alambic Investment Management's 13F filing for Q1 2017, filed 9 May 2017.